Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InMed Pharmaceuticals Inc. (INM : NSDQ)

• Company Description    InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $1.72 Daily Weekly Monthly 20 Day Moving Average: 4,947,562 shares Shares Outstanding: 3.31 (millions) Market Capitalization: $5.70 (millions) Beta: 0.57 52 Week High: $5.50 52 Week Low: $0.58 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 125.69% 114.67% 12 Week 95.45% 80.69% Year To Date 62.26% 50.05%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1445 885 West Georgia St. - VANCOUVER,A1 V6C 3E8 CAN ph: 604-669-7207 fax: - ir@inmedpharma.com http://www.inmedpharma.com

• General Corporate Information    Officers Eric A. Adams - Chief Executive Officer; President and Director Netta Jagpal - Chief Financial Officer Andrew Hull - Chairman and Director Bryan Baldasare - Director Nicole Lemerond - Director Peer Information InMed Pharmaceuticals Inc. (GSAC) InMed Pharmaceuticals Inc. (CASIF) InMed Pharmaceuticals Inc. (ALCD.) InMed Pharmaceuticals Inc. (OMNN) InMed Pharmaceuticals Inc. (CGPI.) InMed Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 457637700 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 09/28/26 Share - Related Items Shares Outstanding: 3.31 Most Recent Split Date: 11.00 (0.05:1) Beta: 0.57 Market Capitalization: $5.70 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/28/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.83 Price/Cash Flow: - Price / Sales: 0.99 EPS Growth vs. Year Ago Period: 64.43% vs. Previous Quarter: -35.29% Sales Growth vs. Year Ago Period: -26.26% vs. Previous Quarter: -26.79% ROE 03/31/26 - -80.85 12/31/25 - -74.15 09/30/25 - -86.48 ROA 03/31/26 - -68.11 12/31/25 - -62.48 09/30/25 - -70.76 Current Ratio 03/31/26 - 3.12 12/31/25 - 5.94 09/30/25 - 6.95 Quick Ratio 03/31/26 - 3.12 12/31/25 - 5.30 09/30/25 - 6.37 Operating Margin 03/31/26 - - 12/31/25 - -133.81 09/30/25 - -136.39 Net Margin 03/31/26 - - 12/31/25 - -132.87 09/30/25 - -135.49 Pre-Tax Margin 03/31/26 - -186.17 12/31/25 - -132.87 09/30/25 - -135.49 Book Value 03/31/26 - 2.08 12/31/25 - 3.42 09/30/25 - 4.13 Inventory Turnover 03/31/26 - 4.52 12/31/25 - 3.51 09/30/25 - 3.38 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.01 09/30/25 - 0.02 Debt-to-Capital 03/31/26 - 0.44 12/31/25 - 1.27 09/30/25 - 1.82

Powered by Zacks Investment Research ©